ArticleNeurosurgery2021
Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study.
Article in Neurosurgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Single fraction and hypofractionated radiosurgery for perioptic meningiomas-tumor control and visual outcomes: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- Hypofractionated Gamma Knife Icon Radiosurgery for Perioptic Meningiomas: Clinical and Radiological Outcomes in a Series of 100 Patients.Life (Basel, Switzerland) · 2026Article
- Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances.Current oncology reports · 2026Review
- Multidisciplinary treatment strategy optimization and long-term prognosis in spheno-orbital meningiomas: a multicenter retrospective study.Neurosurgical review · 2026Article
- Single-Fraction Stereotactic Radiosurgery for Benign Perioptic Meningiomas: A Strategy for Long-Term Tumor Control and Radiation-Induced Optic Neuropathy Avoidance With a 10-Year Follow-up.Journal of Korean medical science · 2026Article
- Optimizing outcome in radiosurgery for spheno-orbital meningioma: the critical role of planning quality. Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Radiosurgery for Intracranial Meningiomas: A Review of Anatomical Challenges and an Update on the Evidence.Cancers · 2024Review
- Frailty in intracranial meningioma resection: the risk analysis index demonstrates strong discrimination for predicting non-home discharge and in-hospital mortality.Journal of neuro-oncology · 2024Article
- Stereotactic radiotherapy of radiation-induced meningioma previously irradiated retrobulbar for Graves' ophthalmopathy: A case report.Radiology case reports · 2024Article
- Comments: neurosurgery and radiation oncology advances have improved visual outcomes for skull base meningioma patients.Journal of neuro-oncology · 2023Article
- Combined helical tomotherapy and Gamma Knife stereotactic radiosurgery for high-grade recurrent orbital meningioma: a case report.Frontiers in oncology · 2023Article
- Tumors Involving the Infratemporal Fossa: A Systematic Review of Clinical Characteristics and Treatment Outcomes.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
backgroundStereotactic radiosurgery (SRS) is increasingly used for management of perioptic meningiomas.
objectiveTo study the safety and effectiveness of SRS for perioptic meningiomas.
methodsFrom 12 institutions participating in the International Radiosurgery Research Foundation (IRRF), we retrospectively assessed treatment parameters and outcomes following SRS for meningiomas located within 3 mm of the optic apparatus.
resultsA total of 438 patients (median age 51 yr) underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) perioptic meningiomas. Median treatment volume was 8.01 cm3. Median prescription dose was 12 Gy, and median dose to the optic apparatus was 8.50 Gy. A total of 405 patients (93%) underwent single-fraction SRS and 33 patients (7%) underwent hypofractionated SRS. During median imaging follow-up of 55.6 mo (range: 3.15-239 mo), 33 (8%) patients experienced tumor progression. Actuarial 5-yr and 10-yr progression-free survival was 96% and 89%, respectively. Prescription dose of ≥12 Gy (HR: 0.310; 95% CI [0.141-0.679], P = .003) and single-fraction SRS (HR: 0.078; 95% CI [0.016-0.395], P = .002) were associated with improved tumor control. A total of 31 (10%) patients experienced visual decline, with actuarial 5-yr and 10-yr post-SRS visual decline rates of 9% and 21%, respectively. Maximum dose to the optic apparatus ≥10 Gy (HR = 2.370; 95% CI [1.086-5.172], P = .03) and tumor progression (HR = 4.340; 95% CI [2.070-9.097], P < .001) were independent predictors of post-SRS visual decline.
conclusionSRS provides durable tumor control and quite acceptable rates of vision preservation in perioptic meningiomas. Margin dose of ≥12 Gy is associated with improved tumor control, while a dose to the optic apparatus of ≥10 Gy and tumor progression are associated with post-SRS visual decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.